Active Pharmaceutical Industry: Upcoming Technological Innovations | Active Pharmaceutical Ingredients Market - The Pos | Page 11

Novartis International AG (Switzerland), is another leading player in this market. The
co pa y’s strengths lie in its strong brand recognition and robust product portfolio. the
company invests a significant amount of its revenue in R&D activities. In 2015, the
company invested 18.0% of its total revenue (USD 8.9 billion) on R&D. This significant
investment in R&D enables the company to launch innovative and technologically
advanced products in the market.
Novartis also focuses on inorganic growth strategies to sustain its foothold in the market.
For instance, in June 2016, Novartis entered into a licensing and collaboration agreement
with Xencor (U.S.), a biopharmaceutical company that develops engineered monoclonal
antibodies. The purpose of this agreement was to develop bispecific antibodies for
treating cancer.
https://www.marketsandmarkets.com/Market-Reports/API-Market-263.html